Competition Matters

HSR threshold adjustments and reportability

When Congress passed the Hart-Scott-Rodino Antitrust Improvements Act of 1976, it created minimum dollar thresholds to limit the burden of premerger reporting. In 2000, it amended the HSR statute to require the annual adjustment of these thresholds based on the change in gross national product. As a result, reportability under the Act changes from year to year as the statutory thresholds adjust. The PNO fields many questions about the upcoming adjustments to the HSR thresholds from parties whose transactions may take place around the time of the revisions.

The power of competition advocacy: Dynamic pricing offers real benefits for residential electricity customers

This will come as no shock to anyone familiar with the Federal Trade Commission’s policy and advocacy function: FTC staff has a long history of advocating for effective competition and consumer protection in electricity markets.

Looking for something?

If you regularly use FTC.gov to find cases, speeches, reports or such, then you’ve probably noticed a few changes. We know -- change is hard. But with added features like drop-down menus and filters, finding what you need on the new FTC.gov should be easier than ever.

A New Year's message for 2014

Every new year brings an opportunity for reflection on the past and the future. 2014 is a milestone for the Federal Trade Commission as it marks 100 years since President Woodrow Wilson signed the FTC Act into law. We will be commemorating our centennial throughout the year by reflecting on our history of fostering honest business practices and robust competition in the marketplace.

Location and value of patents

Each year, the Premerger Notification Office answers thousands of letters, phone calls, and emails regarding the Hart-Scott-Rodino rules, giving informal advice on the potential reportability of transactions and help in completing the HSR Notification and Report Form. 

Competition to reduce the costs of biologic medicines

When faced with a major illness, patients usually want the best medicine available, regardless of cost. In some cases, next-generation “biologic” medicines may be the best treatments available. Unfortunately, these critical treatments can be very expensive. For example, Herceptin, used to treat breast cancer, can cost more than $50,000 a year; Remicade, which treats rheumatoid arthritis, more than $10,000 a year.

Welcome to the new FTC.gov!

With the agency’s 100th anniversary just around the corner, we’re giving the public an updated FTC.gov. The revised site provides better access to information about us and our efforts to protect consumers and promote competition. 

When we designed the site, we listened to advice from lots of regular people, as well as experts in the competition and consumer protection communities. The result? An overhauled FTC.gov that is more powerful, easy to use and attractive.

Welcome to Competition Matters

Welcome to Competition Matters, the FTC’s newest blog for all things competition. We hope to become your go-to spot for the latest insights and events from the Bureau of Competition, the Bureau of Economics, and the Office of Policy Planning. We’ll also have occasional missives from our Office of International Affairs on their work to build cooperative relationships with foreign enforcement agencies, and to promote sound approaches to common problems. Along the way, we’ll highlight offerings by competition folks throughout the agency that may not get front page attention.

Pages